abstract |
Disclosed are ERK inhibitors of formula 1.0: (wherein the chemical formula should be inserted herein as appearing in the summary in writing) and pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that may have a bridge or fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using a compound of formula 1.0. The invention also provides at least one (eg, 1, 2 or 3, 1 or 2, usually 1) compound of formula 1.0 (eg, any one of Embodiment Nos. 1-143). Also provided is a pharmaceutical composition comprising an effective amount of as described) and a pharmaceutically acceptable carrier. |